Aptus Capital Advisors LLC Has $29.17 Million Stake in Stryker Co. (NYSE:SYK)

Aptus Capital Advisors LLC lifted its position in shares of Stryker Co. (NYSE:SYK) by 20.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 80,748 shares of the medical technology company’s stock after purchasing an additional 13,947 shares during the period. Aptus Capital Advisors LLC’s holdings in Stryker were worth $29,171,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Aigen Investment Management LP purchased a new stake in Stryker in the 3rd quarter worth about $493,000. Savvy Advisors Inc. grew its stake in Stryker by 29.7% in the 3rd quarter. Savvy Advisors Inc. now owns 1,388 shares of the medical technology company’s stock valued at $501,000 after buying an additional 318 shares in the last quarter. Ashton Thomas Private Wealth LLC raised its holdings in Stryker by 3.3% during the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 14,610 shares of the medical technology company’s stock valued at $5,278,000 after acquiring an additional 464 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Stryker by 2.9% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,143,573 shares of the medical technology company’s stock worth $413,127,000 after acquiring an additional 32,491 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Stryker in the third quarter worth $362,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Up 1.3 %

Shares of NYSE SYK traded up $4.87 during mid-day trading on Tuesday, hitting $383.73. The stock had a trading volume of 370,364 shares, compared to its average volume of 1,248,934. The business has a 50 day moving average price of $361.83 and a two-hundred day moving average price of $346.06. Stryker Co. has a 1 year low of $276.60 and a 1 year high of $385.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a market cap of $146.29 billion, a P/E ratio of 40.61, a price-to-earnings-growth ratio of 2.83 and a beta of 0.91.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same period last year, the company earned $2.46 EPS. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. On average, equities analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on SYK. Evercore ISI raised their target price on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Royal Bank of Canada boosted their price objective on shares of Stryker from $386.00 to $400.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. increased their target price on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, Stifel Nicolaus lowered their price objective on Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $393.65.

Insider Activity

In other news, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Viju Menon sold 600 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now owns 9,069 shares in the company, valued at approximately $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 67,381 shares of company stock valued at $24,825,275. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.